Further studies with kappa opioid receptor agonists and antagonists should clarify whether disproportionate gain of body weight on highly caloric foods could be influenced by pharmacological manipulation of kappa opioid receptors and answer whether agonists could be used as a potential treatment strategy against obesity in overweight patients. This evidence concerns the gene OPRK1 and obesity due to melanocortin 4 receptor deficiency.